| |
|
|
A BILL TO BE ENTITLED
|
|
|
AN ACT
|
| |
|
|
relating to the Texas Pharmaceutical Initiative; authorizing fees. |
|
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
|
SECTION 1. Subtitle D, Title 10, Government Code, is |
|
|
amended by adding Chapter 2177 to read as follows: |
|
|
CHAPTER 2177. TEXAS PHARMACEUTICAL INITIATIVE |
|
|
Sec. 2177.001. DEFINITIONS. In this chapter: |
|
|
(1) "Board" means the governing board of the |
|
|
initiative. |
|
|
(2) "Fund" means the Texas Pharmaceutical Initiative |
|
|
fund. |
|
|
(3) "Generic biological product" means a biological |
|
|
product approved pursuant to an application under Section 351(k), |
|
|
Public Health Service Act (42 U.S.C. Section 262(k)). |
|
|
(4) "Generic drug" means a prescription drug approved |
|
|
pursuant to an application under Section 505(j), Federal Food, |
|
|
Drug, and Cosmetic Act (21 U.S.C. Section 355(j)). |
|
|
(5) "Initiative" means the Texas Pharmaceutical |
|
|
Initiative established under this chapter. |
|
|
Sec. 2177.002. TEXAS PHARMACEUTICAL INITIATIVE. (a) The |
|
|
Texas Pharmaceutical Initiative is established to provide |
|
|
cost-effective access to prescription drugs and other medical |
|
|
supplies for: |
|
|
(1) employees, dependents, and retirees of public |
|
|
higher education systems and institutions; |
|
|
(2) Employees Retirement System of Texas members; |
|
|
(3) Teacher Retirement System of Texas members; |
|
|
(4) persons confined by the Texas Department of |
|
|
Criminal Justice or the Texas Juvenile Justice Department; |
|
|
(5) recipients of medical assistance under Chapter 32, |
|
|
Human Resources Code; and |
|
|
(6) enrollees of the child health plan program under |
|
|
Chapter 62, Health and Safety Code. |
|
|
(b) A state entity or managed care organization as defined |
|
|
by Chapter 533, Government Code, that provides health benefit plan |
|
|
coverage to individuals described by Subsection (a) as the entity |
|
|
or managed care organization determines appropriate may elect to |
|
|
provide access to prescription drugs and other medical supplies |
|
|
under the initiative. |
|
|
Sec. 2177.003. BOARD. (a) The initiative is governed by a |
|
|
board composed of: |
|
|
(1) the executive commissioner of the Health and Human |
|
|
Services Commission or the executive commissioner's designee; |
|
|
(2) the executive director of the Employees Retirement |
|
|
System of Texas or the executive director's designee; |
|
|
(3) the executive director of the Teacher Retirement |
|
|
System of Texas or the executive director's designee; |
|
|
(4) three members appointed by the governor; |
|
|
(5) one member appointed by the governor from a list of |
|
|
three names submitted by the lieutenant governor; |
|
|
(6) one member appointed by the governor from a list of |
|
|
three names submitted by the speaker of the house of |
|
|
representatives; and |
|
|
(7) the chancellor of The University of Texas System, |
|
|
or the chancellor's designee, who serves in an ex-officio capacity. |
|
|
(b) A vacancy on the board shall be filled in the same manner |
|
|
as the original appointment. |
|
|
(c) The appointed board members serve staggered six-year |
|
|
terms. |
|
|
(d) The governor shall designate the presiding officer of |
|
|
the board. |
|
|
(e) A board member serves without compensation but may be |
|
|
reimbursed for travel and other actual and reasonable expenses |
|
|
incurred in the performance of the member's duties on the board. |
|
|
(f) The board is administratively attached to the Health and |
|
|
Human Services Commission. |
|
|
Sec. 2177.004. DUTIES OF BOARD. (a) The board shall: |
|
|
(1) develop and implement the initiative and related |
|
|
programs established by this chapter; |
|
|
(2) establish procedures and policies for the |
|
|
administration of the initiative; |
|
|
(3) establish procedures to document compliance by |
|
|
board members and personnel with applicable laws governing |
|
|
conflicts of interest; |
|
|
(4) ensure that a program or entity created under this |
|
|
chapter meets any applicable licensing or accreditation |
|
|
requirements under state or federal law; and |
|
|
(5) recommend rules necessary to implement this |
|
|
chapter for adoption by the executive commissioner of the Health |
|
|
and Human Services Commission. |
|
|
(b) To carry out the purposes of this chapter the board may: |
|
|
(1) execute contracts and other instruments and |
|
|
conduct all activities the board determines necessary for those |
|
|
purposes; |
|
|
(2) authorize one or more board members to execute |
|
|
contracts and other instruments on behalf of the board; |
|
|
(3) establish a committee or other similar entity to |
|
|
exercise powers delegated by the board and exercise any other |
|
|
administrative duties or powers as the board considers necessary; |
|
|
(4) employ an executive director and necessary |
|
|
personnel to provide administrative support; and |
|
|
(5) award grants to public or private persons to |
|
|
implement the initiative. |
|
|
(c) The board may refrain from establishing a program or |
|
|
entity under this chapter if the board determines that |
|
|
establishment is not feasible with current resources or considering |
|
|
other state-funded programs. |
|
|
(d) A contract or agreement executed under this chapter must |
|
|
comply with Chapter 2254, if applicable. |
|
|
Sec. 2177.005. PHARMACY BENEFIT MANAGER. (a) The board |
|
|
shall contract for a statewide pharmacy benefit manager, as |
|
|
provided by Subchapter H, Chapter 2158, to provide cost-effective |
|
|
prescription drugs through the establishment of a pharmacy network |
|
|
to state entities served by the initiative. |
|
|
(b) The pharmacy benefit manager shall provide pricing |
|
|
transparency, a pass-through of all rebates and fees, and fair and |
|
|
equitable pricing to a pharmacy that participates in the pharmacy |
|
|
benefit manager's pharmacy network. |
|
|
(c) The pharmacy benefit manager shall contract with |
|
|
appropriate persons to: |
|
|
(1) provide an evidence-based benefit design, a prior |
|
|
authorization process, and a new drug review process; and |
|
|
(2) partner with suppliers, pharmaceutical |
|
|
manufacturers, and group purchasing organizations for competitive |
|
|
acquisition of prescription drugs and medical supplies. |
|
|
Sec. 2177.006. DISTRIBUTION OF PRESCRIPTION DRUGS AND |
|
|
MEDICAL SUPPLIES. (a) The board shall establish and implement a |
|
|
central service center and an associated network of satellite |
|
|
distribution facilities to provide prescription drugs and medical |
|
|
supplies to individuals described by Section 2177.002 for state |
|
|
entities that elect to participate in the initiative. The center |
|
|
must: |
|
|
(1) be constructed to withstand extreme weather |
|
|
conditions, natural disasters, and power outages; |
|
|
(2) be capable of providing disaster preparedness and |
|
|
response resources statewide; and |
|
|
(3) include a mail order pharmacy and specialty |
|
|
pharmacy. |
|
|
(b) The central service center may assess an inventory |
|
|
storage charge, transaction fees, or other fees on persons |
|
|
obtaining prescription drugs and medical supplies from the center |
|
|
to support the center's distribution and other operational costs, |
|
|
including overhead and margin. |
|
|
(c) The mail order and specialty pharmacy established in the |
|
|
central service center may assess delivery and handling fees on |
|
|
persons receiving prescription drugs from the pharmacy. |
|
|
Sec. 2177.007. PHARMACEUTICAL ADVANCED PREPARATION |
|
|
FACILITY. (a) The board shall establish a pharmaceutical advanced |
|
|
preparation facility to serve as an outsourcing facility in |
|
|
compliance with Section 503B, Federal Food, Drug, and Cosmetic Act |
|
|
(21 U.S.C. Section 353b), to: |
|
|
(1) manufacture and provide compounded drugs; |
|
|
(2) provide chimeric antigen receptor T-cell |
|
|
treatment and other gene therapies, including precision medicine; |
|
|
and |
|
|
(3) provide advanced laboratories for quality |
|
|
control, preparation, and compounding of drugs in support of |
|
|
innovative therapeutics and drug research. |
|
|
(b) The pharmaceutical advanced preparation facility shall |
|
|
be operated by an organization established by the board that is |
|
|
exempt from federal income taxation under Section 501(a), Internal |
|
|
Revenue Code of 1986, by being listed as an exempt entity under |
|
|
Section 501(c)(3) of that code. |
|
|
(c) The pharmaceutical advanced preparation facility may |
|
|
charge fees to persons to whom the facility provides drugs, |
|
|
treatment, supplies, or other services to support the operational |
|
|
costs of the facility, including overhead and margin. |
|
|
Sec. 2177.008. ADVANCED HEALTH CARE COST AND CLAIMS |
|
|
ANALYTIC SERVICES. (a) The board shall contract with a person to |
|
|
provide advanced health care claims analytics software to support |
|
|
the programs and entities created by this chapter and to support |
|
|
population health research. |
|
|
(b) The board shall develop criteria for the evaluation of |
|
|
applications or proposals submitted by a person seeking to contract |
|
|
with the board under this section. |
|
|
Sec. 2177.009. GENERIC BIOLOGICAL PRODUCT AND GENERIC DRUG |
|
|
MANUFACTURING FACILITY. (a) The board may enter into an agreement |
|
|
with a person to establish a facility that manufactures generic |
|
|
biological products and generic drugs in compliance with any |
|
|
requirements of the federal Food and Drug Administration. In |
|
|
entering into the agreement, the board shall prioritize savings and |
|
|
access to affordable medications. |
|
|
(b) The board shall develop criteria for the evaluation of |
|
|
applications or proposals submitted by a person seeking to contract |
|
|
with the board under this section. |
|
|
Sec. 2177.010. CONFIDENTIALITY OF CERTAIN INFORMATION. Any |
|
|
information received by the board, a program or entity created by |
|
|
this chapter, a state entity participating in the initiative, or a |
|
|
contractor or agent of the board that if directly or indirectly |
|
|
disclosed is likely to compromise the financial, competitive, or |
|
|
proprietary nature of the information, is confidential and not |
|
|
subject to disclosure under Chapter 552. |
|
|
Sec. 2177.011. TEXAS PHARMACEUTICAL INITIATIVE FUND. (a) |
|
|
The Texas Pharmaceutical Initiative fund is created as a trust fund |
|
|
to be held by the comptroller outside the state treasury. |
|
|
(b) The fund consists of: |
|
|
(1) money from gifts, grants, and donations to the |
|
|
fund; |
|
|
(2) any additional legislative appropriations of |
|
|
money for the purposes of the fund; and |
|
|
(3) interest, dividends, and other income of the fund. |
|
|
(c) The board may only use money in the fund to carry out the |
|
|
purposes of this chapter. |
|
|
(d) The board shall develop procedures for administration |
|
|
and approval of expenditures of the fund. |
|
|
Sec. 2177.012. FUNDING. The board may accept gifts, |
|
|
grants, and donations from any public or private source for the |
|
|
purpose of carrying out this chapter. |
|
|
Sec. 2177.013. ANNUAL REPORT. Not later than December 31 of |
|
|
each year, the board shall submit to the legislature a written |
|
|
report on: |
|
|
(1) the activities and objectives of the initiative; |
|
|
(2) any cost savings for state entities that |
|
|
participate in the initiative; and |
|
|
(3) any recommendations for legislative or other |
|
|
action. |
|
|
Sec. 2177.014. SUNSET PROVISION. The board and the |
|
|
initiative established under this chapter are subject to Chapter |
|
|
325, Government Code (Texas Sunset Act). Unless continued in |
|
|
existence as provided by that chapter, the board and the initiative |
|
|
are abolished and this chapter expires September 1, 2035. |
|
|
SECTION 2. This Act takes effect immediately if it receives |
|
|
a vote of two-thirds of all the members elected to each house, as |
|
|
provided by Section 39, Article III, Texas Constitution. If this |
|
|
Act does not receive the vote necessary for immediate effect, this |
|
|
Act takes effect September 1, 2023. |
|
|
|
|
|
* * * * * |